Gilgamesh, a New York City-based biotechnology company developing psychedelic drugs to treat mental illness, is “in full swing” to close on a Series B round of funding in the next few months, according to Laszlo Kiss, Gilgamesh’s Chief Business Officer and Head of Research. This round follows up on the company’s $27 million Series A…